There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on BioDelivery (BDSI – Research Report) and Axsome Therapeutics (AXSM – Research Report) with bullish sentiments.
In a report issued on January 13, Tim Lugo from William Blair maintained a Buy rating on BioDelivery. The company’s shares closed last Monday at $5.98.
According to TipRanks.com, Lugo is a 5-star analyst with an average return of 14.2% and a 49.5% success rate. Lugo covers the Healthcare sector, focusing on stocks such as Biohaven Pharmaceutical Holding Co, Collegium Pharmaceutical, and BioMarin Pharmaceutical.
Currently, the analyst consensus on BioDelivery is a Strong Buy with an average price target of $8.00, implying a 32.5% upside from current levels. In a report issued on January 3, Cantor Fitzgerald also maintained a Buy rating on the stock with a $8.00 price target.
Axsome Therapeutics (AXSM)
In a report issued on January 13, Myles Minter from William Blair maintained a Buy rating on Axsome Therapeutics. The company’s shares closed last Monday at $91.33.
Minter has an average return of 233.6% when recommending Axsome Therapeutics.
According to TipRanks.com, Minter is ranked #307 out of 5850 analysts.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Axsome Therapeutics with a $140.25 average price target, implying a 50.8% upside from current levels. In a report issued on December 30, H.C. Wainwright also reiterated a Buy rating on the stock with a $200.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.